Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10

Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10

This study examined the role of brachytherapy boost (BT-boost) and external beam radiotherapy (EBRT) in intermediate- to high-risk prostate cancer, especially in patients with very high-risk factors (VHR: T3b–4 or Gleason score 9–10) as patients with double very high-risk factors (VHR-2: T3b–4 and G...

Full description

Bibliographic Details
Main Authors: Hideya Yamazaki, Gen Suzuki, Koji Masui, Norihiro Aibe, Daisuke Shimizu, Takuya Kimoto, Kei Yamada, Koji Okihara, Takashi Ueda, Tsukasa Narukawa, Takumi Shiraishi, Atsuko Fujihara, Ken Yoshida, Satoaki Nakamura, Takashi Kato, Yasutoshi Hashimoto, Haruumi Okabe
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
radiotherapy
brachytherapy boost
very high-risk
T3b–4
Gleason 9–10
prostate cancer
Online Access:https://www.mdpi.com/2072-6694/14/12/2976

Similar Items

Similar Items